Literature DB >> 25562108

Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro.

Wim F P M Van den Hof1, Ainhoa Ruiz-Aracama2, Anke Van Summeren3, Danyel G J Jennen4, Stan Gaj5, Maarten L J Coonen6, Karen Brauers7, Will K W H Wodzig8, Joost H M van Delft9, Jos C S Kleinjans10.   

Abstract

In order to improve attrition rates of candidate-drugs there is a need for a better understanding of the mechanisms underlying drug-induced hepatotoxicity. We aim to further unravel the toxicological response of hepatocytes to a prototypical cholestatic compound by integrating transcriptomic and metabonomic profiling of HepG2 cells exposed to Cyclosporin A. Cyclosporin A exposure induced intracellular cholesterol accumulation and diminished intracellular bile acid levels. Performing pathway analyses of significant mRNAs and metabolites separately and integrated, resulted in more relevant pathways for the latter. Integrated analyses showed pathways involved in cell cycle and cellular metabolism to be significantly changed. Moreover, pathways involved in protein processing of the endoplasmic reticulum, bile acid biosynthesis and cholesterol metabolism were significantly affected. Our findings indicate that an integrated approach combining metabonomics and transcriptomics data derived from representative in vitro models, with bioinformatics can improve our understanding of the mechanisms of action underlying drug-induced hepatotoxicity. Furthermore, we showed that integrating multiple omics and thereby analyzing genes, microRNAs and metabolites of the opposed model for drug-induced cholestasis can give valuable information about mechanisms of drug-induced cholestasis in vitro and therefore could be used in toxicity screening of new drug candidates at an early stage of drug discovery.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cholestasis; Cyclosporin A; Hepatotoxicity; Metabonomics; MicroRNA; Transcriptomics

Mesh:

Substances:

Year:  2015        PMID: 25562108     DOI: 10.1016/j.tiv.2014.12.016

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  8 in total

Review 1.  Experimental design and reporting standards for metabolomics studies of mammalian cell lines.

Authors:  Sarah Hayton; Garth L Maker; Ian Mullaney; Robert D Trengove
Journal:  Cell Mol Life Sci       Date:  2017-07-01       Impact factor: 9.261

2.  In vitro prediction of drug-induced cholestatic liver injury: a challenge for the toxicologist.

Authors:  Mathieu Vinken
Journal:  Arch Toxicol       Date:  2018-03-24       Impact factor: 5.153

3.  New microRNA Biomarkers for Drug-Induced Steatosis and Their Potential to Predict the Contribution of Drugs to Non-alcoholic Fatty Liver Disease.

Authors:  Mireia López-Riera; Isabel Conde; Laia Tolosa; Ángela Zaragoza; José V Castell; María J Gómez-Lechón; Ramiro Jover
Journal:  Front Pharmacol       Date:  2017-01-25       Impact factor: 5.810

4.  Untargeted Metabolomic Analysis of Rat Neuroblastoma Cells as a Model System to Study the Biochemical Effects of the Acute Administration of Methamphetamine.

Authors:  Garth L Maker; Tobias Green; Ian Mullaney; Robert D Trengove
Journal:  Metabolites       Date:  2018-06-07

5.  The human hepatocyte TXG-MAPr: gene co-expression network modules to support mechanism-based risk assessment.

Authors:  Giulia Callegaro; Steven J Kunnen; Panuwat Trairatphisan; Solène Grosdidier; Marije Niemeijer; Wouter den Hollander; Emre Guney; Janet Piñero Gonzalez; Laura Furlong; Yue W Webster; Julio Saez-Rodriguez; Jeffrey J Sutherland; Jennifer Mollon; James L Stevens; Bob van de Water
Journal:  Arch Toxicol       Date:  2021-10-09       Impact factor: 5.153

6.  Identification of key genes and pathways between mild-moderate and severe asthmatics via bioinformatics analysis.

Authors:  Xiaolu Wu; Ran Li; Qu Xu; Feng Liu; Yue Jiang; Min Zhang; Meiling Tong
Journal:  Sci Rep       Date:  2022-02-15       Impact factor: 4.996

7.  Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury.

Authors:  Lindsey Devisscher; Mathieu Vinken; Eva Gijbels; Vânia Vilas-Boas; Pieter Annaert; Tamara Vanhaecke
Journal:  Arch Toxicol       Date:  2020-03-10       Impact factor: 5.153

Review 8.  The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role?

Authors:  Paula Iruzubieta; Maria Teresa Arias-Loste; Lucía Barbier-Torres; Maria Luz Martinez-Chantar; Javier Crespo
Journal:  Biomed Res Int       Date:  2015-12-28       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.